StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.05−0.06 (-0.06%)

Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –

Kiniksa Pharmaceuticals International pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Kiniksa Pharmaceuticals International's pe ratio was 98.7× on Nov 11, 2026, against 94.5× a year earlier. Over the last 3 years it ranged from 4.1× to 970.8×, with a median of 76.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202698.7×+7.1
2025Dec 31, 202591.7×−240.8
2024Jul 31, 2024332.5×+327.8
2023Oct 31, 20234.7×−2.8
2022Dec 30, 20227.5×–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?